These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 9855175)
1. Safety profiles of leading nonsteroidal anti-inflammatory drugs. Rothstein R Am J Med; 1998 Nov; 105(5A):39S-43S. PubMed ID: 9855175 [TBL] [Abstract][Full Text] [Related]
2. Economic and gastrointestinal safety comparisons of etodolac, nabumetone, and oxaprozin from insurance claims data from patients with arthritis. Simon LS; Zhao SZ; Arguelles LM; Lefkowith JB; Dedhiya SD; Fort JG; Johnson KE Clin Ther; 1998; 20(6):1218-35; discussion 1192-3. PubMed ID: 9916614 [TBL] [Abstract][Full Text] [Related]
4. Safety of the nonselective NSAID nabumetone : focus on gastrointestinal tolerability. Bannwarth B Drug Saf; 2008; 31(6):485-503. PubMed ID: 18484783 [TBL] [Abstract][Full Text] [Related]
5. The efficacy, tolerability, and safety of 1200 mg/d of oxaprozin and 1500 mg/d of nabumetone in the treatment of patients with osteoarthritis of the knee. Makarowski W; Weaver A; Rubin B; Caldwell J; McMahon FG; Noveck RJ; Lee D; Offenberg H; Sack M; Sikes D; Trapp R; Rush S; Kuss M; Ganju J; Bocanegra TS; Ratliff JM Clin Ther; 1996; 18(1):114-24. PubMed ID: 8851458 [TBL] [Abstract][Full Text] [Related]
6. Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin. Brinker A; Goldkind L; Bonnel R; Beitz J Drugs Aging; 2004; 21(7):479-84. PubMed ID: 15132714 [TBL] [Abstract][Full Text] [Related]
7. Health-related quality-of-life effects of oxaprozin and nabumetone in patients with osteoarthritis of the knee. Zhao SZ; Dedhiya SD; Bocanegra TS; Fort JG; Kuss ME; Rush SM Clin Ther; 1999 Jan; 21(1):205-17. PubMed ID: 10090436 [TBL] [Abstract][Full Text] [Related]
8. [Properties and features of nabumetone]. Davies NM; McLachlan AJ Drugs; 2000; 59 Spec No 1():25-33. PubMed ID: 10841070 [TBL] [Abstract][Full Text] [Related]
9. [Gastrointestinal tolerance of nonsteroidal anti-inflammatory agents]. Bannwarth B Drugs; 2000; 59 Spec No 1():17-23. PubMed ID: 10841069 [TBL] [Abstract][Full Text] [Related]
10. [Rationale for using nabumetone and clinical experience]. Roth SH Drugs; 2000; 59 Spec No 1():35-41. PubMed ID: 10841071 [TBL] [Abstract][Full Text] [Related]
11. Nabumetone, an effective anti-inflammatory agent, lacks gastrointestinal irritancy in the rat when dosed orally for one month: comparison with tiaprofenic acid and etodolac. Melarange R; Gentry C; Blower PR; Toseland CD; Spangler R Eur J Rheumatol Inflamm; 1994; 14(2):15-22. PubMed ID: 7744129 [TBL] [Abstract][Full Text] [Related]
12. Nabumetone: a clinical appraisal. Helfgott SM Semin Arthritis Rheum; 1994 Apr; 23(5):341-6. PubMed ID: 8036523 [TBL] [Abstract][Full Text] [Related]
13. A review of selected newer nonsteroidal anti-inflammatory drugs. Cummings DM; Amadio P Am Fam Physician; 1994 Apr; 49(5):1197-202. PubMed ID: 8154406 [TBL] [Abstract][Full Text] [Related]
15. Rationalizing cyclooxygenase (COX) inhibition for maximal efficacy and minimal adverse events. Freston JW Am J Med; 1999 Dec; 107(6A):78S-88S; discussion 89S. PubMed ID: 10628597 [TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal safety profile of nabumetone: a meta-analysis. Huang JQ; Sridhar S; Hunt RH Am J Med; 1999 Dec; 107(6A):55S-61S; discussion 61S-64S. PubMed ID: 10628594 [TBL] [Abstract][Full Text] [Related]
17. Newer, safer nonsteroidal anti-inflammatory drugs. Rational NSAID selection for arthritis. Bensen W; Zizzo A Can Fam Physician; 1998 Jan; 44():101-2, 105-7. PubMed ID: 9481468 [TBL] [Abstract][Full Text] [Related]
18. Nabumetone. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases. Friedel HA; Langtry HD; Buckley MM Drugs; 1993 Jan; 45(1):131-56. PubMed ID: 7680981 [TBL] [Abstract][Full Text] [Related]
20. Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Rainsford KD Am J Med; 1999 Dec; 107(6A):27S-35S; discussion 35S-36S. PubMed ID: 10628591 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]